BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a BioSante presentation and corporate discussion are available at

Stephen M. Simes, president and CEO of BioSante presented an in-depth view of the Company’s strategy, development pipeline and clinical milestones, during an interview by Elemer Piros, Ph.D., senior biotechnology analyst at Rodman & Renshaw, LLC (NASDAQ: RODM). The topics discussed included an overview of BioSante and specifically a thorough discussion of LibiGel ® (testosterone gel), in development for the treatment of female sexual dysfunction, as well as BioSante’s portfolio of GVAX cancer vaccines.

“This fireside chat is among the most far-reaching discussions we’ve ever had about our products and we are pleased to make it accessible. I would encourage all those interested in learning more about BioSante to visit the link,,” said Simes.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer vaccines, two of which have been granted orphan drug designations, currently in several Phase II clinical trials, at minimal cost to BioSante, its 2A/Furin and other technologies. Additional information is available online at:

Copyright Business Wire 2010